Hamlet BioPharma (HAMLET B.SL) Action Cours

Hamlet BioPharma AB engages in the research and development of pharmaceutical products focusing on tumor cells. The company is headquartered in Lund, Skane and currently employs 8 full-time employees. The company went IPO on 2015-10-23. The firm provides new therapeutic solutions using a peptide-based molecular approach for targeting and killing tumour cells with greater precision. Its synthetic drug candidate Alpha1H kills tumor cells quickly, both in the laboratory and in animal models and in treated patients, where the response can be measured already within a few hours. The other product BAMLET kills cancer cells and has shown effects against growing tumor tissue, especially for colon cancer. Hamlet Pharma is therefore driving the development of BAMLET as a future drug against cancer. The firm intends to establish production of BAMLET primarily for clinical studies of the treatment/prevention of colon cancer in the gastrointestinal tract and oral cancer in the oral cavity.